Zoetis (ZTS) Long-Term Debt Repayments (2016 - 2023)

Zoetis (ZTS) posted quarterly Long-Term Debt Repayments of $1.4 billion for Q1 2023, up 170.0% quarter-over-quarter from $500.0 million in Q4 2020.

Zoetis (ZTS) Long-Term Debt Repayments (2016 - 2023) Analysis & Trends

Zoetis (ZTS) has reported Long-Term Debt Repayments for 4 consecutive years, with $1.4 billion the latest figure, recorded in Q1 2023.

In Q1 2023, Long-Term Debt Repayments changed N/A year-over-year to $1.4 billion; the TTM figure through Dec 2023 stood at $1.4 billion (changed N/A YoY), while the FY2025 annual figure was $1.4 billion, changed N/A from the prior year.
Long-Term Debt Repayments advanced to $1.4 billion in Q1 2023 per ZTS's latest filing, from $500.0 million in the prior quarter.
Across five years, Long-Term Debt Repayments topped out at $1.4 billion in Q1 2023 and bottomed at $500.0 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	-
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	-156,847.56
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	-
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	Alkermes	8.02 Bn	7.37 Bn	397.90 Mn	-

Download Data